PHARMASHOTS NEWSWIRE

Apr 18, 2025 HONG KONG, April 18, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that ebdarokimab, an investigational monoclonal antibody developed by the company, has received marketing approval from the National Medical

4/17/2025 Collaboration combines BigHat's AL/ML-powered MillinerTM platform with Lilly's expertise in drug discovery to develop high-quality next-generation antibodies. SAN MATEO, CA (April 17th, 2025)– BigHat Biosciences (“BigHat”), a biotechnology company with

Apr 17, 2025 NORTHBROOK, Ill., April 17, 2025 /PRNewswire/ -- Endevica Bio, a privately held company developing first-in-class peptide drug candidates, announced today the dose administration for the first patient in a Phase 2 trial for its experimental drug TCMCB07 (B07) to prevent wei

17 April 2025 London, 17 April 2025 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces it has acquired the FDA-approved Abbreviated New Drug Application (ANDA) for trametinib tablets from Novugen. Hikma also announces it has entered into a co

April 17, 2025 If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are indicated for all other anti-VEGF therapies Potential for as frequent as monthly d

April 17, 2025 Orforglipron is the first small molecule GLP-1 to successfully complete a Phase 3 trial, lowering A1C by an average of 1.3% to 1.6% across doses The investigational once-daily oral pill reduced weight by an average 16.0 lbs (7.9%) at the highest dose in a key secondary